PARADIGHM (Physicians Advancing Disease Knowledge in Hypoparathyroidism): A Registry for Patients With Chronic Hypoparathyroidism
Phase of Trial: Phase IV
Latest Information Update: 22 May 2018
At a glance
- Drugs Parathyroid hormone (Primary)
- Indications Hyperparathyroidism
- Focus Adverse reactions; Pharmacodynamics
- Acronyms PARADIGHM
- Sponsors Shire
- 22 May 2018 Study design presented at the 20th European Congress of Endocrinology (ECE 2018), according to a Shire plc media release.
- 16 Feb 2018 Planned End Date changed from 1 Jun 2032 to 30 Jun 2035.
- 16 Feb 2018 Planned primary completion date changed from 1 Jun 2030 to 30 Jun 2035.